$89.76 Billion Blood Plasma Derivatives Markets – Global Opportunities Analysis and Industry Forecast, 2021-2030


DUBLIN, May 04, 2022–(BUSINESS WIRE)–The report “Blood Plasma Derivatives Market by Product Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030” has been added to from ResearchAndMarkets.com offer.

The global Blood Plasma Derivatives Market size was valued at USD 36.471 Billion in 2020 and is projected to reach USD 89.767 Billion by 2030, growing at a CAGR of 9.4% from 2021 to 2030.

Factors driving the growth of the blood plasma derivatives market include increasing prevalence of life-threatening diseases such as immunodeficiency diseases and hemophilia, increased awareness of blood and plasma donation, and growth in adoption of products derived from blood plasma.

Additionally, other factors responsible for the growth of plasma-derived derivatives are increased awareness of blood and plasma donation, increase in the geriatric population, and increased adoption of blood plasma-derived products. Additionally, market players focus on manufacturing different blood plasma derivative products.

For example, in April 2020, Biotest, a pharmaceutical company, announced the launch of a life-saving drug, derived from the blood plasma of a COVID-19 patient. Additionally, increasing prevalence of the geriatric population, which is more vulnerable to chronic diseases, is accelerating the growth of the blood plasma derivatives market.

Additionally, rising disposable income and developing pharmaceutical industry for manufacturing plasma-derived products are expected to boost the market growth. Additionally, the expansion of numerous clinical studies on various types of products to assess their safety and efficacy is propelling the growth of the market.

For example, in February 2022, the U.S. Food and Drug Administration (FDA) announced clinical research activities to improve the safety of blood plasma-derived products, such as proteins used to treat systemic disorders. immune and bleeding disorders.

Rising number of approvals for plasma-derived products and rising number of pharmaceutical manufacturing companies are the key factors that are further driving the growth of the blood plasma derivatives market. However, the high cost of plasma derivative therapy and the risk of associated side effects after the use of plasma derivatives is hampering the market growth. Conversely, the development of superior methods of preserving plasma derivatives along with advanced fractionation processes and the presence of an untapped market in emerging economies are expected to provide lucrative growth opportunities for the market.

The blood plasma derivatives market is segmented into type, application, end-user, and region. On the basis of type, the market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin and others. Immunoglobulin segment dominated the market in 2020, and this trend is expected to continue during the forecast period, due to the increase in R&D activities related to the manufacturing of plasma-derived products in the pharmaceutical industry and increasing prevalence of immune diseases.

Based on application, the blood plasma derivatives market is categorized into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease (vWD) and other applications. The immunodeficiency disease segment is expected to lead during the forecast period, owing to the increase in the prevalence of immune diseases and the development of advanced drugs by the pharmaceutical industry.

By end-user, the market is categorized into hospital, clinic, and other end-users. The hospital segment was the main contributor in 2020 and is expected to maintain its lead over the forecast period, due to the increase in the number of hospitals and the initiatives taken by governments and private organizations to develop the healthcare sector. health.

The COVID-19 outbreak is expected to have a positive impact on the growth of the global plasma derivatives market. The COVID-19 pandemic has strained health systems around the world. Meanwhile, in August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for convalescent plasma for the treatment of hospitalized patients with COVID-19.

Antibodies or plasma are taken from donors who have recovered from COVID-19. It may contain antibodies against SARS-CoV-2, which help suppress viral replication. Thus, the upsurge in the demand for plasma-derived products for the treatment of infectious diseases has had a positive impact on the market growth.

Main results of the study

  • By type, immunodeficiency disorder was the largest contributor to the blood plasma derivatives market in 2020

  • Based on the application, another application dominated the market in 2020 and is expected to continue this trend during the forecast period

  • According to end-user, hospital segment dominated the blood plasma derivatives market in 2020

  • Regionally, North America generated the largest revenue share in 2020, however, Asia-Pacific is expected to grow at the highest CAGR during the forecast period

  • North America won a major share of the blood plasma derivatives market in 2020 and is expected to continue to dominate over the forecast period, owing to the increasing number of approvals for blood plasma derivatives and the increase in the number of key players to manufacture plasma derivatives. medication. However, Asia-Pacific is expected to register the highest CAGR of 110% from 2021 to 2030, due to rising prevalence of immune diseases, heightened awareness of plasma derivatives and increased spending health.


Market players

By type

  • Albumin

  • Factor VIII

  • Factor IX

  • Immunoglobulin

  • hyperimmune globulin

  • Others

By request

Per end user

  • Hospitals

  • Clinics

  • Other end users

By region

  • North America

  • WE

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • The rest of Europe

  • Asia Pacific

  • Japan

  • China

  • Australia

  • India

  • South Korea

  • Rest of Asia-Pacific


  • Brazil

  • Saudi Arabia

  • South Africa

  • Rest of LAMEA

For more information about this report visit https://www.researchandmarkets.com/r/d8ih32

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220504005800/en/


Laura Wood, Senior Press Officer
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900


Comments are closed.